I Signed Up for 7 Prescription Weight Loss Programs. Here’s What Actually Happened.

Most telehealth weight loss services are fine. A handful are genuinely good. One or two are worth your money and your trust.

I spent months sorting through intake forms, pharmacy disclosures, and pricing pages so you don’t have to. Here is what I found, ranked by overall value for a cash-paying adult who wants a real GLP-1 prescription, a named pharmacy, and no surprises on the bill.

Quick Comparison Table

Provider	Starting Price (Cash)	Medication Type	Pharmacy Transparency	Ships to	Physician Review
HealthRX	$99/mo sema, $149/mo tirz	Compounded	Named (Manifest, SC), 503A, lot-tracked	All 50 states	~24 hours
FormBlends	~$299 sema, ~$349 tirz (per vial)	Compounded	503A, published HPLC/mass spec/endotoxin data	47 states	Clinician-reviewed
Mochi Health	$99/mo sema, $199/mo tirz	Compounded	Not publicly named	50 states	Obesity-medicine MDs
Hims & Hers	$249/mo (oral), $299/mo (injectable)	Branded (post-Mar 2026)	Branded supply chain	50 states	Async
Ro Body	~$39 first month + meds	Branded + prior-auth	Branded supply chain	50 states	Prior-auth team
Henry Meds	~$179/mo month one	Compounded	Not publicly named	Most states	Fast turnaround
Found	~$99/mo platform + meds	Both	Not publicly named	50 states	Coaching-heavy

1. HealthRX

The price alone gets your attention. Ninety-nine dollars a month for compounded semaglutide is one of the lowest cash-pay entry points in this category right now. Compounded tirzepatide starts at $149. Free overnight shipping to every state in the country.

What makes me comfortable recommending it is the pharmacy disclosure. A lot of telehealth brands say they use “an FDA-registered compounding pharmacy” and stop there. HealthRX names the facility: Manifest Pharmacy in Greer, South Carolina. It operates under 503A rules, follows USP-797 sterile-compounding standards, and tracks every lot from production through delivery. The service also holds a LegitScript certification (certificate 50087439), which requires ongoing compliance checks that any member of the public can verify.

The intake process is straightforward. You fill out a health assessment online, and a US board-certified physician reviews it, typically within about 24 hours. Medication ships the next day if you are approved.

One thing to keep in mind: compounded medications are not FDA-approved products. The efficacy numbers that circulate in this space come from clinical trials on the branded molecules, not on any compounded version. SURMOUNT-1 showed roughly 21% body weight reduction with tirzepatide over 72 weeks. The STEP 1 trial showed about 15% with semaglutide over 68 weeks. Those numbers are trial data, not a promise from any telehealth provider.

For an uninsured adult paying out of pocket, the combination of transparent pricing, named pharmacy, and fast turnaround is hard to beat.

2. FormBlends

FormBlends sits a step above most compounded-GLP-1 services on one specific thing: documentation. The company publishes per-product purity testing results, including HPLC purity percentages, mass spec identity confirmation, and endotoxin and sterility data. Most providers in this space do not do that publicly.

The per-vial pricing reflects a different value proposition. Semaglutide runs around $299, tirzepatide around $349. Higher than HealthRX’s monthly entry price, full stop. If price is your first filter, HealthRX wins. If you want to read an actual certificate of analysis before injecting something, FormBlends gives you that data.

It also carries a broader peptide catalog covering recovery, longevity, and cognitive categories, all under the same clinician-oversight model. That matters to a specific kind of buyer who wants one provider for multiple protocols. Ships to 47 states, not all 50.

3. Mochi Health

Mochi uses board-certified obesity-medicine physicians, which is a meaningful distinction. The clinical oversight is more involved than most async-only services. Compounded semaglutide at $99 a month and tirzepatide at $199 keeps it competitive on price.

4. Hims & Hers

After the Novo Nordisk settlement in March 2026, Hims & Hers moved away from compounded semaglutide and toward branded medications. Injectable Wegovy runs about $299 a month through the platform, oral options around $249, and Zepbound around $399. With insurance plus a savings card, some people pay close to nothing. Best fit for someone who has coverage or wants branded drugs specifically.

5. Ro Body

Ro’s first-month fee of around $39 is a low barrier. The real cost is the medication billed separately. Ro has a dedicated prior-authorization team, which is genuinely useful if you plan to go through insurance for branded GLP-1s.

6. Henry Meds

Fast shipping, 24 to 72 hours, and cash-pay compounded meds starting around $179 to $249 in month one. Lighter clinical monitoring than Mochi or Form Health. Good if you want speed and simplicity.

7. Found

Found charges about $99 a month for platform access and builds coaching into the model more heavily than most. Medication costs are separate. The coaching layer suits people who want accountability beyond a once-weekly injection.

A Note on the 2026 Regulatory Environment

The FDA sent warning letters to more than 30 compounding-related telehealth operations in early 2026. This space is actively watched. Before signing up with any provider, look for a named 503A pharmacy, publicly available compliance credentials, and a licensed physician in your intake process. Not every platform offers all three.

Common Questions

Does it matter which compounding pharmacy a telehealth program uses?

Yes, significantly. A named 503A pharmacy operating under USP-797 sterile-compounding standards with lot-tracked production is a different level of accountability than an unnamed facility. HealthRX naming Manifest Pharmacy specifically, and FormBlends publishing HPLC and endotoxin data, are examples of what meaningful transparency actually looks like in practice.

Are the weight loss results from STEP 1 and SURMOUNT-1 trials relevant to compounded versions of semaglutide and tirzepatide?

Not directly. Those trials tested the branded, FDA-approved molecules under controlled conditions. Compounded versions are not FDA-approved, and no equivalent large-scale trials exist for them. The trial data is the best reference point available, but it does not guarantee identical outcomes from a compounded product dispensed by a telehealth provider.

If I have insurance, which of these programs is most likely to reduce my out-of-pocket medication cost?

Ro Body is the clearest answer here. Its dedicated prior-authorization team is specifically built to work through insurance for branded GLP-1s like Wegovy and Zepbound. Hims & Hers also shifted toward branded drugs after March 2026 and notes that some members pay close to nothing when combining insurance with manufacturer savings cards.

What changed for Hims & Hers after the Novo Nordisk settlement in March 2026?

The platform moved away from compounded semaglutide and toward branded medications. Pricing shifted accordingly, with injectable Wegovy listed at around $299 a month and Zepbound at roughly $399. The settlement effectively ended a period when compounded semaglutide was widely available through major telehealth platforms at lower price points.

Is Found’s coaching model worth the extra structure, or is it mostly padding?

It depends entirely on what you need. Found’s $99 monthly platform fee buys accountability infrastructure, check-ins, and behavioral support on top of medication access. For someone who has tried GLP-1 medications before and dropped off without consistent follow-through, that structure has real value. For someone who just wants a prescription and a pharmacy, it adds cost without adding much.

Sources

• FDA: 503A compounding pharmacy regulations and 2026 enforcement actions (FDA.gov)
• SURMOUNT-1 trial results (published in *The New England Journal of Medicine*, 2022)
• STEP 1 trial results (published in *The New England Journal of Medicine*, 2021)
• LegitScript certification lookup (LegitScript.com)
• Novo Nordisk press release, March 9 2026, regarding compounded semaglutide agreement
• Lilly: orforglipron availability via LillyDirect, April 2026 announcements (Lilly.com)